Last updated: February 23, 2026
What is NDC 54436-0250?
NDC 54436-0250 corresponds to Firdapse (amifampridine), a drug approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder characterized by muscle weakness.
Market Landscape
Indication and Patient Population
- Target condition: LEMS.
- Prevalence: Approximately 3.4 per million people in the U.S.[1].
- Patient estimate: Around 1,100 to 1,500 patients in the U.S., given no cure exists and treatment persists long-term.
Competitive Environment
- Existing treatments: No FDA-approved alternatives for LEMS.
- Off-label use: Symptomatic treatments like 3,4-diaminopyridine (DIP), but with variable access and approval status.
- Recent approvals: No direct newcomers since Firdapse’s FDA approval in 2018.
Regulatory and Manufacturing Factors
- FDA approval date: August 2018.
- Manufacturership: Commercially supplied by Catalyst Pharmaceuticals.
- Pricing regulation: No strict government price controls; prices influenced by market exclusivity and insurance coverage.
Market Size and Revenue Potential
| Factor |
Details |
Data Year |
Source |
| U.S. LEMS Patients |
1,100–1,500 |
2023 |
[1] |
| Estimated Annual Treatment Cost per Patient |
$28,000 |
2023 |
[2] |
| Total U.S. Market Revenue |
$30.8M–$42M |
2023 |
Calculated |
Note: The cost includes drug acquisition, monitoring, and supportive therapies.
Market Penetration
- Estimates: Firdapse captures about 40–60% of the eligible LEMS population, considering prescriber adoption rates and insurance coverage.
- Projected revenue (2023): Approximately $12M to $25M.
Market Growth Factors
- Rising diagnosis awareness: May expand patient count modestly.
- Insurance reimbursement: Critical for penetration; favorable coverage encourages sales.
- Potential pipeline drugs: No direct competitors approved yet; future entrants could diminish Firdapse’s share.
Price Projections
Current Pricing Environment
- Wholesale acquisition cost (WAC): Approximately $3,067 per 30-count pack (30 mg tablets)[2].
- Monthly cost per patient: Around $7,500, considering typical dosing (~30 mg daily).
Short-term Price Trends
- Stable pricing: No significant evidence of price hikes since approval, dictated by market exclusivity.
- Price sensitivity: Low, due to the rarity-driven classification and limited substitutes.
Long-term Price Outlook
| Scenario |
Assumption |
Price Range |
Rationale |
| Conservative |
Maintains current WAC |
$3,000–$3,200 per 30-day supply |
Market stability, no new entrants |
| Moderate |
Slight decrease with increased competition |
$2,800–$3,000 |
Biosimilar or alternative therapies emerge |
| Aggressive |
Price reductions mandated by policy or reimbursement constraints |
$2,500–$2,800 |
Price control measures or insurance negotiations |
Revenue Projections (Next 5 Years)
| Year |
Revenue (Low Estimate) |
Revenue (High Estimate) |
Assumptions |
| 2024 |
$10M |
$20M |
Market share stabilization |
| 2025 |
$10–$20M |
$22–$24M |
Slight increases in diagnosis and coverage |
| 2026 |
$10–$22M |
$24–$26M |
Market saturation plateau |
Key Influences on Market and Price
- Regulatory developments: New approvals or restrictions can alter pricing and patient access.
- Insurance landscapes: Changes in coverage policies, particularly for orphan drugs; Medicaid and Medicare reimbursement rates.
- Emerging competitors: Biosimilars or oral therapies could erode market share.
- Pricing policies: Legislation like ICER evaluations or drug price caps may impact future prices.
Summary
Firdapse (amifampridine) maintains a niche but stable market driven by the rarity of LEMS and lack of alternatives. Price levels are expected to stay flat or slightly decline depending on market dynamics and policy pressures. Revenue prospects are contingent on new diagnostics, prescriber adoption, and insurance reimbursement strategies.
Key Takeaways
- Estimated U.S. patient base: 1,100–1,500.
- Current annual treatment revenue: roughly $12–$25 million.
- Price points: around $3,000 per 30 days.
- Future growth hinges on market access, biosimilar entry, and regulatory factors.
FAQs
Q1: Will competition emerge for Firdapse in the near future?
A: There are no approved warants for direct competitors. Future biosimilars or alternative therapies might enter the market, impacting prices.
Q2: How does insurance coverage affect market size?
A: Favorable insurance coverage increases patient access, boosting revenue; coverage restrictions can limit market size.
Q3: What regulatory risks could influence prices?
A: Policy changes, such as drug price caps or ICER evaluations, could pressures prices downward.
Q4: Is there potential for off-label or expanded indications?
A: Currently, Firdapse's approved indication is limited to LEMS. Expanded use would require additional trials and approvals, which are unlikely in the short term.
Q5: How do pricing trends compare with other orphan drugs?
A: Similar drugs maintain high prices due to small patient populations, with minimal fluctuations unless policy or competition intervenes.
References
[1] Thompson, A. et al. (2022). Rare Disease Prevalence Estimates. J Rare Disord.
[2] Catalyst Pharmaceuticals. (2023). Firdapse Pricing and Market Data.
[3] FDA. (2018). Drug Approval: Amifampridine.
Note: All data are estimates based on current market understanding and publicly available sources.
